Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-05-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第四届董事会第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on adjustments and actions related to the company's stock incentive plans, including restricted stock repurchase prices, stock option exercise prices, and cancellation of certain stock options. It references compliance with laws and company articles but does not contain financial statements or detailed financial data. The document is a formal opinion related to board meeting matters, specifically concerning stock incentive plans and their adjustments. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a simple announcement or certification but a detailed management-related opinion on stock incentive adjustments. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or management, including stock incentive plan adjustments and related approvals.
2020-05-20 Chinese
第四届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the third meeting of the fourth Supervisory Board of the company. It details the approval of adjustments to stock incentive plans, stock option plans, and the repurchase and cancellation of restricted stocks and stock options. The document includes voting results and references to announcements published on a regulatory disclosure website. It does not contain financial statements or detailed financial analysis but rather reports on governance decisions related to stock incentives and supervisory board resolutions. This fits the category of Board/Management Information (MANG), as it concerns decisions and changes approved by the company's supervisory board regarding management incentive plans.
2020-05-20 Chinese
关于参加2020年广东辖区上市公司投资者集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (595 characters) about the company's participation in an investor collective reception day event organized by regulatory and industry bodies. It mentions the date and format of the event and invites investors to participate. There is no financial data, no detailed report, no voting results, no management changes, or other substantive filings. The document is an announcement related to investor relations and communication, not a report or transcript. Given the short length and nature, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2020-05-15 Chinese
2019年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from a company regarding the implementation of its 2019 annual equity distribution plan, including cash dividends and stock dividends. It specifies the dividend amount, record date, ex-dividend date, and details about share capital changes. The document is relatively short (2194 characters) and focuses on the dividend distribution details rather than presenting full financial statements or comprehensive annual results. It does not contain detailed financial performance data or management discussion. Therefore, it is best classified as a Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder information.
2020-05-13 Chinese
未来三年（2020年-2022年）股东分红回报规划
Regulatory Filings Classification · 90% confidence The document is a detailed plan outlining the company's shareholder dividend return policy for the years 2020 to 2022. It discusses principles, conditions, proportions, and timing of cash and stock dividends, as well as the formulation and adjustment mechanisms of the dividend plan. It references regulatory guidelines from the China Securities Regulatory Commission and the company's articles of association. The document is not a financial report, earnings release, or announcement of voting results, but rather a formal policy document related to dividend distribution planning. It does not fit into categories like dividend amount notice (DIV) because it is a multi-year planning document rather than a specific dividend announcement. It is also not a regulatory filing or report publication announcement since it contains substantive policy content. The best fitting category is therefore a Regulatory Filing (RNS) as a general regulatory announcement about dividend policy planning that does not fit other specific categories.
2020-05-12 Chinese
前次募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Usage Verification Report." It is an audit-style report issued by an accounting firm (致同会计师事务所) verifying the usage of previously raised funds by 健帆生物科技集团股份有限公司. The document includes detailed tables and explanations about the amounts raised, usage, investment projects, and benefits realized from the fundraising. It references compliance with China Securities Regulatory Commission rules regarding fundraising usage reports. The document is 7,184 characters long, which is substantial and contains detailed financial and operational data about the use of capital raised. This is not a simple announcement or a certification letter but a standalone audit/verification report on the use of capital raised. It does not represent a full annual or interim financial report but rather a specific audit report on fundraising usage. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2019
2020-05-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.